Feasibility Pilot of Accelerated Stimulation With TMS for Treatment of Major Depressive Disorder (FAST-MDD)
Recruiting
This is a mixed-methods study that includes three steps. The first is a focus group to collect opinions and feedback about implementation of aTMS among clinicians, technicians, nurses, and other clinical staff at the St. Louis Park (SLP) clinic who are experienced with delivering TMS. The second is the delivery of a set of questionnaires delivered to TMS patients at the SLP clinic who are awaiting the start of their TMS series. The third is the delivery of aTMS utilizing the MagVenture TMS devic... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
08/11/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Major Depressive Disorder
Evaluation of Miricorilant on Liver Fat in Patients With MASLD
Recruiting
A Phase 1, Open-Label Study Evaluating the Effect of Miricorilant on Hepatic Lipids in Patients with Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/11/2025
Locations: University of Missouri, Columbia, Missouri
Conditions: Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Non-alcoholic Fatty Liver Disease (NAFLD)
Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)
Recruiting
The primary objective of this study is to assess the 6-month safety of DBV712 250 micrograms (mcg) in subjects 1 through 3 years of age with peanut allergy.
Gender:
ALL
Ages:
Between 1 year and 3 years
Trial Updated:
08/11/2025
Locations: AllerVie Clinical Research, Birmingham, Alabama +57 locations
Conditions: Allergy, Peanut Allergy
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
Recruiting
The purpose of the study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the treatment of alopecia areata. Alopecia areata is a disease that causes hair loss on the scalp, face, and areas of the body. Ritlecitinib is approved in many countries at a dose of 50 mg (milligram) taken by mouth once a day for the treatment of patients 12 years and older with severe alopecia areata. This study will look at both the 50 mg dose and a 100 mg dose. This study is s... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
08/11/2025
Locations: Burke Pharmaceutical Research, Hot Springs, Arkansas +88 locations
Conditions: Alopecia Areata
Vitamin A Supplementation in Allogeneic Stem Cell Transplantation.
Recruiting
The investigators hypothesize that single oral high dose supplementation with vitamin A will reduce the incidence of moderate-severe chronic graft-versus-host disease (GVHD) compared with placebo.
Gender:
ALL
Ages:
All
Trial Updated:
08/11/2025
Locations: Moffitt Cancer Center, Tampa, Florida +2 locations
Conditions: Graft Vs Host Disease, Vitamin A Deficiency, Vitamin D Deficiency
Neurofeedback to Reduce Spontaneous Recovery of Threat Expectancy
Recruiting
This study tests the efficacy of a new behavioral intervention with the goal of reducing spontaneous recovery of threat expectancy in healthy adults. This real-time functional magnetic resonance imaging (fMRI) neurofeedback intervention delivers feedback based on a functional connection between the prefrontal cortex and the hippocampus.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
08/11/2025
Locations: Princeton Neuroscience Institute, Princeton, New Jersey
Conditions: Healthy
Self Neuro-modulation Therapy for Major Depressive Disorder (MDD) With Anhedonia
Recruiting
The purpose of this research is to learn more about a new treatment for individuals with Major Depressive Disorder (MDD) with heightened symptoms of anhedonia (i.e. loss of pleasure or interest in activities). The treatment is called Prism, and it is a software device intended for a novel form of neurofeedback training to be used in a clinic setting. During this study, the subject will use different techniques to measure brain activities, including magnetic resonance imaging (MRI) and electroen... Read More
Gender:
ALL
Ages:
Between 22 years and 75 years
Trial Updated:
08/11/2025
Locations: Novus Psychiatry, Tuscaloosa, Alabama +1 locations
Conditions: Depressive Disorder, Major
Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis
Recruiting
Psoriatic arthritis (PsA) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, stiffness, and swelling. Symptoms can get worse and go away for periods of time. This study will evaluate the efficacy and safety of targeted therapies through a series of substudies, for the treatment of active psoriatic arthritis and to assess the changes in disease symptoms. The therapies being assessed in this sub-study are risankizumab and lutiki... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Newport Huntington Medical Group /ID# 272764, Huntington Beach, California +21 locations
Conditions: Psoriatic Arthritis
Non-interventional Pre-screening Protocol Aims to Evaluate Participants for Potential Trial Eligibility in Future Clinical Trials/Studies Focusing on Metabolic and Psychiatric Health.
Recruiting
DOVE-MET-COME-100 is a single site prescreening survey study designed to identify adults who may be eligible for future industry-sponsored clinical trials. A physician will oversee the informed consent process, after which participants will be surveyed on demographics, medical history, current health conditions and symptoms. The study team may also collect basic health information, including vital signs, urine drug tests, blood samples and pregnancy tests (if applicable). A physician will review... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Clindove Research LLC, Brooklyn, New York
Conditions: Cardiovascular Diseases, Metabolic Syndrome, Obesity, Prediabetes, Mental Health Disorders, Endocrine Dysfunction, Type 2 Diabetes Mellitus (T2DM), Chronic Kidney Disease (CKD)
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
Recruiting
This is an open-label study to be conducted in adults with hypertriglyceridemia (HTG) and severe hypertriglyceridemia (SHTG). Each participant must have completed all required visits per protocol in the parent study AROAPOC3-3001 (NCT05089084), AROAPOC3-3003 (NCT06347003), AROAPOC3-3004 (NCT06347016) or AROAPOC3-3009 (NCT06347133). All eligible participants will receive plozasiran administered subcutaneously (SC) approximately every 3 months for 24 months. Participants will be counseled to remai... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Research Site 1, Miami Lakes, Florida +6 locations
Conditions: Hypertriglyceridemia
Cryo NerVe Block Extremity AmputatioN RegIStry for Post Operative and pHantom Limb Pain
Recruiting
The goal of this Registry is to see how the device is used when freezing nerves during an amputation procedure.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Elliot Hospital, Manchester, New Hampshire
Conditions: Amputation, Amputation of Lower Limb, Amputation of Upper Limb, Amputation, Limb Loss, Amputation, Traumatic/Surgery, Cryo Analgesia
The Prism Conformity Trial for Post-Traumatic Stress Disorder in Adolescents
Recruiting
Prism is a software as a medical device (SaMD) to be prescribed by clinicians as an adjunct to the standard of care treatment of patients with PTSD. The Prism software device runs on a laptop using an EEG signal input (g).Nautilos PRO (K171669). The primary objective of the study is to extend the use of the FDA cleared Prism for PTSD (K222101) to an adolescent population and to confirm the safety of fifteen (15±3) EEG-NF training sessions using the Prism software in reducing PTSD-related sympto... Read More
Gender:
ALL
Ages:
Between 12 years and 21 years
Trial Updated:
08/11/2025
Locations: NYU Langone Health, New York, New York
Conditions: Post-Traumatic Stress Disorder in Adolescence